Newsroom

Dendrogenix will participate in BIO-Europe 2026, taking place in Cologne, Germany, from November 9 to 11.

During the event, our team will share the latest progress of DX243, Dendrogenix’s lead clinical candidate currently being evaluated in a Phase IIa clinical trial in patients with age-related hearing loss and reduced speech intelligibility in noise.

Following the successful completion of Phase I and the initiation of Phase IIa, Dendrogenix is entering an important stage in the clinical development of DX243. We look forward to discussing our development strategy and exploring partnerships and financing opportunities to support the next steps of the program and the broader potential of our pipeline.